DENGUE VIRUS LYSATE SEROTYPE 3
Dengue virus lysate Serotype 3 (H87 strain) has been manufactured to provide a consistent source of Dengue virus antigens. This material has been produced by culturing Dengue virus serotype 3 (H87 strain) in the Vero cell line. The Dengue virus lysate is supplied purified and heat inactivated. This product is suitable for use in a broad range of applications including immunoassay research and development.
PRODUCT DETAILS – DENGUE VIRUS LYSATE SEROTYPE 3
- Dengue virus serotype 3 lysate from vero cells.
- Following culture, the virus is purified by sucrose density gradient ultracentrifugation.
- Purified virions were lysed in 0.6M KCl containing 0.5% Triton X-100, and then subjected to heat inactivation.
BACKGROUND
Dengue virus (DENV) is a single-stranded RNA virus that belongs to the genus Flavivirus, which includes Zika virus, West Nile virus and Japanese Encephalitis virus. Dengue infection is transmitted to humans by mosquitoes, primarily Aedes aegypti species.
Dengue is an emerging disease that is a leading cause of illness and death in the tropics and subtropics, with more than one-third of the world’s population living in areas at risk of transmission. It is febrile illness that affects infants, young children and adults with symptoms appearing 3-14 days after the infective bite. Symptoms range from mild fever, to incapacitating high fever, with severe headache, pain behind the eyes, muscle and joint pain, and rash.
Severe dengue (also known as dengue hemorrhagic fever) is a potentially lethal complication that is characterized by fever, abdominal pain, persistent vomiting, bleeding and breathing difficulty (WHO). Dengue infection is caused by any one of four related viruses DEN-1, DEN-2, DEN-3 and DEN-4, also referred to as serotypes, which co-circulate in endemic areas. Infection with one dengue serotype confers lifelong immunity but subsequent infection with other dengue serotypes is associated with an increased risk of developing severe dengue. Early clinical diagnosis and careful clinical management are essential for increasing patient survival.
Currently, there is no antiviral therapy for the treatment of dengue or severe dengue disease. Early diagnosis of dengue and dengue serotypes is a vital step in patient management. However, many of the proteins expressed by Flaviruses are very similar, and serological testing for these viruses can be complicated by problems of cross-reactivity. In this context, the use of highly purified antigens, that are glycosylated and folded as native proteins can be highly important in the development of accurate immunoassays.
